Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF

MLA

DAPA-HF Investigators and Committees, et al. Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. Dec. 2020. EBSCOhost, https://doi.org/10.2337/figshare.13235543.v1.

APA

DAPA-HF Investigators and Committees, John JV McMurray, Pardeep S Jhund, Mikaela Sjöstrand, Anna Maria Langkilde, Olof Bengtsson, Charlotta E.A. Ljungman, Andre Dukát, Mirta Diez, Rudolf A. de Boer, Chern-En Chiang, Michael Böhm, Jan Bělohlávek, Subodh Verma, Scott D Solomon, Marc S Sabatine, Piotr Ponikowski, Felipe A Martinez, Mikhail N Kosiborod, … Silvio E Inzucchi. (2020). Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. https://doi.org/10.2337/figshare.13235543.v1

Chicago

DAPA-HF Investigators and Committees, John JV McMurray, Pardeep S Jhund, Mikaela Sjöstrand, Anna Maria Langkilde, Olof Bengtsson, Charlotta E.A. Ljungman, et al. 2020. “Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF,” December. doi:10.2337/figshare.13235543.v1.